Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for CBD Of Denver's Debt-to-EBITDA or its related term are showing as below:
CBDD's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.64 * Ranked among companies with meaningful Debt-to-EBITDA only.
CBD Of Denver (OTCPK:CBDD) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CBD Of Denver Debt-to-EBITDA Related Terms
CBD Of Denver Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for CBD Of Denver's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBD Of Denver Debt-to-EBITDA Chart
CBD Of Denver Annual Data
Trend
Debt-to-EBITDA
CBD Of Denver Quarterly Data
Debt-to-EBITDA
CBDD vs ASKH, CRCO, PTSX: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CBD Of Denver's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CBD Of Denver Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CBD Of Denver's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CBD Of Denver's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (. 20) EBITDA data.
CBD Of Denver (CBDD) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CBD Of Denver.
Is CBD Of Denver's Debt-to-EBITDA too high?
CBD Of Denver's current Debt-to-EBITDA is 0.00.
How does CBD Of Denver's Debt-to-EBITDA compare to ASKH and CRCO?
CBD Of Denver's Debt-to-EBITDA of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CBD Of Denver. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CBD Of Denver's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CBD Of Denver stock overvalued right now?
CBD Of Denver (CBDD) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CBD Of Denver (CBDD), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CBD Of Denver Inc through its subsidiary, the company operates in the hemp and CBD market, focusing exclusively on wholesale distribution. It provides consulting services related to cultivation, legal, and compliance aspects within the sector. The company offers a full line of hemp oil an CBD products and is a producer and distributor of other products throughout Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBDD has been successfully added to your 
